Abstract:Therapeutic antibody development, manufacturing, and administration face challenges due to high viscosities and aggregation tendencies often observed in highly concentrated antibody solutions. This poses a particular problem for subcutaneous administration, which requires low-volume and high-concentration formulations. The spatial charge map (SCM (mAbs, 8 (1) (2015), pp. 43-48)) and spatial aggregation propensity (SAP (PNAS. 2009; 106:11937–42) are two computational techniques proposed from previous studies to aid in predicting viscosity and aggregation, respectively. These methods rely on structural data derived from molecular dynamics (MD) simulations, which are known to be time-consuming and computationally demanding. DeepSCM (CSBJ. 2022, 20:2143-2152), a deep learning surrogate model to predict SCM scores in the entire variable region, was used to screen high-concentration antibody viscosity. DeepSCM is solely based on sequence information, which facilitates high throughput screening. This study further utilized a dataset of 20,530 antibody sequences to train a convolutional neural network deep learning surrogate model called Deep Spatial Properties (DeepSP). DeepSP directly predicts SAP and SCM scores in different domains of antibody variable regions based solely on their sequences without performing MD simulations. The linear correlation coefficient (R) between DeepSP scores and MD-derived scores for 30 properties achieved values between 0.76 and 0.96 with an average of 0.87 on the test set (N=2053). DeepSP was employed as features to build machine learning models to predict the aggregation rate of 21 antibodies. We observed remarkable results with R = 0.97 and a mean squared error (MSE) of 0.03 between the experimental and predicted aggregation rates, leave-one-out cross-validation (LOOCV) yielded R = 0.75 and MSE = 0.18, which is similar to the results obtained from the previous study using MD simulations. This result demonstrates that the DeepSP approach significantly reduces the computational time required compared to MD simulations. The DeepSP model enables the rapid generation of 30 structural properties that can also be used as features in other research to train machine learning models for predicting various antibody properties, such as viscosity, aggregation, or other properties that can influence their stability, using sequences only. The code and parameters are freely available at

SSH2.0: A Better Tool for Predicting the Hydrophobic Interaction Risk of Monoclonal Antibody

AB-Amy: machine learning aided Amyloidogenic risk prediction of therapeutic antibody light chains

Ab-Amy 2.0: Predicting light chain amyloidogenic risk of therapeutic antibodies based on antibody language model

AbImmPred: An immunogenicity prediction method for therapeutic antibodies using AntiBERTy-based sequence features

DeepSP: Deep Learning-Based Spatial Properties to Predict Monoclonal Antibody Stability

Prediction of immunogenicity for humanized and full human therapeutic antibodies

PROPERMAB: an integrative framework for in silico prediction of antibody developability using machine learning

Machine learning prediction of antibody aggregation and viscosity for high concentration formulation development of protein therapeutics

AREA-AFFINITY : A Web Server for Machine Learning-Based Prediction of Protein–Protein and Antibody–Protein Antigen Binding Affinities

MVSF-AB: Accurate antibody-antigen binding affinity prediction via multi-view sequence feature learning

Predicting deamidation and isomerization sites in therapeutic antibodies using structure-based in silico approaches

DeepSCM: an efficient convolutional neural network surrogate model for the screening of therapeutic antibody viscosity

Highland games: A benchmarking exercise in predicting biophysical and drug properties of monoclonal antibodies from amino acid sequences

Interpretable antibody-antigen interaction prediction by introducing route and priors guidance

Development of QSAR-Improved Statistical Potential for the Structure-Based Analysis of ProteinPeptide Binding Affinities

Accurate prediction of CDR-H3 loop structures of antibodies with deep learning

Predicting the distance between antibody’s interface residue and antigen to recognize antigen types by support vector machine

ProtT5 and random forests-based viscosity prediction method for therapeutic mAbs

Molecular surface descriptors to predict antibody developability: sensitivity to parameters, structure models, and conformational sampling

AI-based IsAb2.0 for antibody design

A New Robust Method for Predicting Hemolytic Toxicity from Peptide Se-quence